PubMed Health⌕ Search

Biomedical subjects

C H Atkinson

Publications and source records attributed to C H Atkinson.

24 records · Page 2Linked to original sources
PubMed1989

Sequential half-body irradiation in lymphomatoid granulomatosis. Report of a case and an immunohistologic study.

A case is presented of a man with ulcerating skin nodules who was diagnosed by histologic and immunohistologic analysis of skin biopsy specimens as having lymphomatoid granulomatosis (LYG). Phenotypic studies showed the majority of the infiltrating cells to be activated CD4+ T-lymphocytes. The disease followed a rapidly progressive course and did not respond to treatment with cytotoxic chemotherapy. The patient developed life-threatening systemic symptoms and involvement of both upper and lower respiratory tracts. After treatment with sequential half-body irradiation he has been in complete remission for 3.5 years.

Adult↗
PubMed1988

High grade nonHodgkin's lymphoma: management with moderate dose combination chemotherapy.

We have reviewed the management of high grade nonHodgkin's lymphoma in a regional cancer centre over an eight year period. Forty-seven patients were referred with diffuse histiocytic, diffuse undifferentiated and lymphoblastic lymphomas or true histiocytic neoplasms. Twenty-six were treated with doxorubicin, cyclophosphamide, vincristine and prednisone (ACOP). The overall complete remission rate was 73%, 83% for stage I and II disease and 62% for stages III and IV. Kaplan-Meier analysis shows 49% surviving at a median follow up time of 23 months (range 1-108 months) with 11 of the 13 survivors continuously disease free. Toxicity was not severe except for one treatment-related death. Most were treated as outpatients. Patients 70 years of age or older were treated less intensively and only 3 of 14 survive. We conclude that treatment with ACOP is simple and effective in the management of high grade nonHodgkin's lymphoma. Currently our protocol includes the same agents, but at higher dosage, with the addition of methotrexate; we believe this should be tested against the recent more intensive, multiagent alternating regimens in a prospective, randomised clinical trial.

Aged↗
PubMed1987

Methotrexate for relapse of metastatic non-seminomatous germ-cell tumours.

Twelve patients with metastatic non-seminomatous germ-cell tumours who relapsed after 3-9 courses (median 7) of cis-platin containing combination chemotherapy, were treated with moderately high-dose methotrexate (1 g m-2) and folinic acid rescue. There was one partial response and the remaining eleven patients showed progression of disease. The patient that responded was one of two patients treated at the time of first relapse. It is concluded that methotrexate does not have a useful role in the salvage treatment of germ-cell tumours relapsing after cis-platin-containing chemotherapy or in patients who are primarily resistant to cis-platin-containing regimes.

Adult↗
PubMed1984

Ameloblastoma of the jaw. A reappraisal of the role of megavoltage irradiation.

Ten patients with ameloblastoma of the jaw were treated with megavoltage irradiation between 1958 and 1982. Seven cases were treated with radiation alone and six responded initially. One patient subsequently recurred and was successfully salvaged surgically. Three patients were treated with combined radiation therapy and surgery. Carefully applied megavoltage irradiation has a useful role in the management of ameloblastoma, particularly in large maxillary tumors with associated destruction of the infrastructure of the maxillary antrum. It is apparent from this series, and from the literature, that the ameloblastoma is not an inherently radioresistant tumor.

Aged↗
PubMedDate not supplied

A risk factor for relapse in Hodgkin's disease: female gender?

A retrospective study of 163 patients with Hodgkin's disease treated between 1969 and 1987 was performed to identify adverse prognostic factors. One hundred and thirty-five patients (83 per cent) attained a complete remission and 42 (31 per cent) of these have relapsed (median follow-up--43 months). Using multivariate analysis, no independent factors predicted for the event of relapse. However, analysis of disease-free survival revealed that females fared significantly worse than males (p less than 0.05) and this was independent of other prognostic variables. Female sex has not been recognized as an independent prognostic factor predictive of inferior survival and inferior disease-free survival.

Antineoplastic Agents↗